The Centers for Medicare and Medicaid Services is directing all Medicare Advantage plans to cover Qalsody for treating ...

Quantitative Alzheimer's risk factors, including accelerated brain changes over time, were detectable in healthy individuals ...

Zilganersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Alexander Disease.

This summary covers key developments in health news, including Mitsubishi Pharma's bidding war, legal actions involving J&J ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a survey on nicotine use in ...

The Centers for Medicare & Medicaid Services (CMS) has mandated Medicare Advantage insurers to provide coverage for Biogen's amyotrophic lateral sclerosis (ALS) medication, Qalsody. This directive ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

Report on how AI is redefining market landscape - The global heparin market size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The market is estimated to grow at a ...